Tuesday, September 06, 2016 12:45:56 PM
Okay, how about a primer on solvency?
Based on its most recent financials, Elite’s current ratio is about 2.3. What that means is they have the ability to pay off their current liabilities by a factor of 2.3X. Any company above 1.00 is doing well, but to be MORE than double is outstanding. If you are unaware, Elite's current ratio is BETTER than Apple, AstraZeneca, Allegan, & Teva pharma.
What other ratios can we offer to show the financial strength of the company? What about the cash ratio? That is the ability to pay off current liabilities with ONLY CASH. Again, anything better than one point zero (1.0) is good (it means the company has one dollar in cash for every dollar in liabilities) and Elite is at 1.51...ONE POINT FIVE ONE DOLLARS FOR EVERY DOLLAR IT OWES!
What point could there be about Elite being solvent? It is about short term liquidity and, as the above clearly shows, Elite has no solvency issues.
Based on its most recent financials, Elite’s current ratio is about 2.3. What that means is they have the ability to pay off their current liabilities by a factor of 2.3X. Any company above 1.00 is doing well, but to be MORE than double is outstanding. If you are unaware, Elite's current ratio is BETTER than Apple, AstraZeneca, Allegan, & Teva pharma.
What other ratios can we offer to show the financial strength of the company? What about the cash ratio? That is the ability to pay off current liabilities with ONLY CASH. Again, anything better than one point zero (1.0) is good (it means the company has one dollar in cash for every dollar in liabilities) and Elite is at 1.51...ONE POINT FIVE ONE DOLLARS FOR EVERY DOLLAR IT OWES!
What point could there be about Elite being solvent? It is about short term liquidity and, as the above clearly shows, Elite has no solvency issues.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
